Semaglutide

What is Semaglutide?

Semaglutide is a synthetic peptide analog of GLP-1 with three key modifications: α-aminoisobutyric acid at position 8 (DPP-4 resistance), a C18 fatty acid conjugation for albumin binding, and a lysine substitution at position 34.

Research mechanism

Published research has examined the following mechanisms:

• GLP-1 receptor agonism — high-affinity binding activates cAMP/PKA signaling.
• Glucose-dependent insulin secretion — in pancreatic beta-cell research models.
• Gastric emptying — effects examined in animal motility studies.
• Half-life extension — fatty acid modification enables strong albumin binding.

Note: All mechanism data is from published research. Not FDA-approved for human use.

Physical properties & handling

Reconstitute 5 mg with 1.0 mL bacteriostatic water (5 mg/mL). GLP-1 class peptides are agitation-sensitive — swirl gently, never vortex. Refrigerate; protect from light; use within 28 days.

Quality specifications (Broceutical Semaglutide)

• Purity: 99.7% typical (HPLC verified)
• Identity: LC-MS/MS with mass accuracy verification
• Endotoxin: <1 EU/mg (LAL)
• Form: Lyophilized powder

Published research references

• Lau J, et al. "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide." J Med Chem. 2015;58(18):7370-80. PubMed PMID: 26308095
• Knudsen LB, Lau J. "The Discovery and Development of Liraglutide and Semaglutide." Front Endocrinol. 2019;10:155. PubMed PMID: 31031702
• PubMed literature search https://pubmed.ncbi.nlm.nih.gov/?term=semaglutide

Broceutical does not endorse or make claims from the above research.